Disciplines: Pharmacists
Hours: 3 Contact Hours
Author(s): William L. Baker, PharmD, FCCP, FACC, BCPS-AQ Cardiology
Peer Reviewer(s):Abir Kanaan, PharmD, RPh
Item#: Y8004
Contents: 1 Course Book (30 pages)
Western Schools is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education

Thrombolytic Therapy: Implications for Patient Management



Price $25.95
Item # Y8004
New
When available, the Online Course format is included with the hard copy, eBook, or audio book formats!

Start Date: September 16, 2016

Expiration Date: September 15, 2019

Clinicians play an important role in managing patients with these conditions who are eligible for high-risk pharmacologic therapies, such as thrombolytics. Specific knowledge of the general information and caveats associated with thrombolytic therapy is vital for optimal patient care outcomes to be achieved. This course is designed for clinicians who provide care to patients currently prescribed thrombolytic medications. The purpose of this course is to increase clinicians’ knowledge of thrombolytic medications so that they can identify the optimal therapy and safely use these medications.

The information in this course was current at the time of publication. Pharmacotherapy is rapidly changing, new pharmaceutical agents are continuously being developed and approved, and older agents are being investigated in new ways; therefore, the clinician should stay abreast of new medications and ongoing research findings and their implications in the delivery of patient care.

Universal Activity Number (UAN) - 0607-0000-16-003-H01-P

Type of Activity - Knowledge

Topic Designator - 01

Course Objectives
  • Identify the relevant pharmacokinetic and pharmacodynamics properties of thrombolytics.
  • Identify and apply the contemporary role of thrombolytics for management of acute ischemic strokes.
  • Describe evidence supporting the use of thrombolytics in acute myocardial infarction.
  • Describe the most appropriate population to receive thrombolytics for treating acute pulmonary embolism.
  • Describe key patient selection and monitoring that can ensure optimal patient outcomes.
  • Describe how a pharmacist can use this information to optimize patient outcomes.

William L. Baker, PharmD, FCCP, FACC, BCPS-AQ Cardiology, is an Assistant Professor of Pharmacy Practice at the University of Connecticut (UConn) School of Pharmacy in Storrs, Connecticut. Dr. Baker received his BS in Pharmacy Studies and Doctor of Pharmacy (PharmD) degrees from the UConn School of Pharmacy in 2000 and 2002, respectively. After being in clinical practice for a number of years, he completed a 2-year cardiovascular pharmacology and outcomes research fellowship at Hartford Hospital in Hartford, Connecticut (2006-2008). He has been on faculty with the UConn School of Pharmacy since 2009. Dr. Baker is a member of a number of pharmacy and cardiology organizations, including the American College of Clinical Pharmacy, American Heart Association, and American College of Cardiology. His clinical experience has focused on caring for adult patients with advanced heart disease who require mechanical therapies or cardiac transplantation. He is the author of more than 100 peer-reviewed publications and frequently presents his research at national/international pharmacy and cardiology conferences. Dr. Baker teaches cardiovascular pharmacology and therapeutics in the UConn School of Pharmacy and holds adjunct appointments as Assistant Professor with both the UConn School of Medicine and UConn Graduate School.

Abir Kanaan, PharmD, RPh, is an Associate Professor of Pharmacy Practice at MCPHS University. She joined the university in 2005 after completing a postgraduate pharmacy practice residency at Umass Memorial Medical Center in Worcester, Massachusetts. Dr. Kanaan also holds an adjunct faculty position in the Department of Medicine at the University of Massachusetts Medical School. She is also affiliated with the Meyers Primary Care Institute, where she is involved in several research projects pertaining to medication safety in the outpatient setting. Dr. Kanaan also serves as a codirector and preceptor for the pharmacy fellowship program in Medication Safety, Quality and Informatics at Saint Vincent Hospital in Worcester, Massachusetts. Dr. Kanaan is also the
Postgraduate Education Committee Program Coordinator for the Worcester and Manchester campuses at MCPHS University. Dr. Kanaan’s practice site is Saint Vincent Hospital in the Coronary Intensive Care unit. She also started and currently leads the hospital’s anticoagulation monitoring program.

  • Contact hours will be awarded for up to one (1) year from date of purchase or by the expiration date indicated above, whichever date comes first.
  • You must score 75% or higher on the final exam and complete the course evaluation to pass this course and receive a certificate of completion.
  • Through our review processes, Western Schools ensures that this course content is presented in a balanced, unbiased manner and is free from commercial influence. It is Western Schools’ policy not to accept commercial support.
  • All persons involved in the planning and development of this course have disclosed no relevant financial relationships or other conflicts of interest related to the course content.
  • William L. Baker has disclosed that he is on the Speaker’s Bureau for Boehringer-Ingelheim. He has agreed to present content that represents current, evidence-based practice and without bias.